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Abstract
Motivation: Gene expression-based prostate cancer gene signatures of poor prognosis are hampered by lack of
gene feature reproducibility and a lack of understandability of their function. Molecular pathway-level mechanisms
are intrinsically more stable and more robust than an individual gene. The Functional Analysis of Individual
Microarray Expression (FAIME) we developed allows distinctive sample-level pathway measurements with utility for
correlation with continuous phenotypes (e.g. survival). Further, we and others have previously demonstrated that
pathway-level classifiers can be as accurate as gene-level classifiers using curated genesets that may implicitly
comprise ascertainment biases (e.g. KEGG, GO). Here, we hypothesized that transformation of individual prostate
cancer patient gene expression to pathway-level mechanisms derived from automated high throughput analyses
of genomic datasets may also permit personalized pathway analysis and improve prognosis of recurrent disease.
Results: Via FAIME, three independent prostate gene expression arrays with both normal and tumor samples were
transformed into two distinct types of molecular pathway mechanisms: (i) the curated Gene Ontology (GO) and (ii)
dynamic expression activity networks of cancer (Cancer Modules). FAIME-derived mechanisms for tumorigenesis
were then identified and compared. Curated GO and computationally generated “Cancer Module” mechanisms
overlap significantly and are enriched for known oncogenic deregulations and highlight potential areas of
investigation. We further show in two independent datasets that these pathway-level tumorigenesis mechanisms
can identify men who are more likely to develop recurrent prostate cancer (log-rank_p = 0.019).
Conclusion: Curation-free biomodules classification derived from congruent gene expression activation breaks
from the paradigm of recapitulating the known curated pathway mechanism universe.
Background
Over the past decade, a plethora of genomic prostate can-
cer signatures have proliferated. A simple PubMed search
reveals over 20,000 entries for genomic signatures ranging
from traditional mRNA, miRNA, and SNP arrays to
whole-exome sequencing. Despite this wealth of signatures
and the fact that prostate cancer remains the second most
common cancer among US men, not a single prostate can-
cer gene signature is available for commercial use. But why
this clinical disconnect? Others and we have identified the
lack of stability, interpretability, and personalization of
these genomic signatures [1,2] as key impediments to their
more widespread adoption.
At its simplest, genomic signatures are merely statisti-
cally significant differences between dichotomized pheno-
types. Yet these phenotypes are heterogeneous and in
prostate cancer have demonstrated low predictive power
of mRNA based genomic signatures [3]. Even with well-
matched, coherent phenotypes, the specter of underpow-
ered statistics due to corrections for multiplicity remains a
very real problem [4].
Fortunately, pathway-level mechanisms offer an elegant
solution in enhancing the power and understandability of
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these genomic signatures. For the sake of clarity, in this
article we use the terms “molecular pathway” and “mole-
cular mechanism” to describe both conceptual and bioin-
formatically derived aggregations of genes such as in the
Gene Ontology as well as protein-protein interaction
subnetworks as referenced above. Work by the Ideker lab
has repeatedly demonstrated the stability of protein net-
work-based signatures over conventional differentially
expressed genes [5]. In other words, perturbations
between two phenotypes lie at the network level and not
at any one genomic marker. Indeed in prostate cancer,
we have demonstrated the conservation of molecular
pathways among multiple prostate gene signatures of
poor prognosis [1].
Nevertheless, the use of pathway-based mechanisms
has been hampered by the difficulty (i) in generating
pathway signatures for an individual patient and (ii) in
unbiasedly and systematically evaluating molecular path-
ways. Traditionally, biologists have conducted a number
of experiments to develop gene sets associated with spe-
cific pathways; however these approaches are rate-limit-
ing when attempting to scale up to a large number of
pathways [6]. Further, previously developed computa-
tional approaches to generate mechanism-anchored
gene expression classifiers either failed to produce accu-
rate classifiers as in the case of straightforward median
or mean-based gene expression [7], or require discrete
group assignments of multiple patients in their learning
algorithm [5,8]. While the latter are exceptionally useful
for better understanding conserved mechanisms of dis-
ease among populations of patients, it does not tell us
what is true for an individual patient. Importantly, to
our knowledge, all these algorithms testing multiple
mechanisms were exclusively validated using human
curated and manually annotated gene sets (e.g. Gene
Ontology).
Ideally then, we would like to leverage the stability of
pathway-level genomics at the level of an individual
patient. The Functional Analysis of Individual Microar-
ray Expression [9], was developed to address these issues
and was used to evaluate head and neck cancer datasets
using curated and pathway annotated. FAIME computes
mechanism scores using rank-weighted gene expression
of an individual sample. Each sample comprises its
“profile of mechanisms”, which allows for correlations
with continuous variables such as survival time. In that
regard, FAIME differs substantially from state of the art
algorithms (e.g. GSEA [10]) that identify mechanisms
across samples rather than within each sample, and are
not designed for correlations.
In this extension of the FAIME algorithm, we
hypothesized that personalized mechanism profiling
using FAIME could be applied to unbiased, curation-
free computationally generated mechanisms (Cancer
Modules). Cancer Modules may provide the ability to
detect pathways that do not have a defined pathway in
the literature and thus are not beholden to existing
domain knowledge. We further hypothesized that they
would be predictive of clinical recurrence, which remains
a hard problem for clinicians treating men with prostate
cancer. We validate this hypothesis in the prostate cancer
domain, for which no mechanism-anchored signatures
have been reported.
Methods
Dataset sources and pre-processing
To determine whether an individualized pathway-level
mechanisms were indeed superior to standard differen-
tially expressed genes, we examined three publically
available independent datasets: Yu [11], Wallace [12], and
Taylor [13] to derive signatures of prostate tumorigen-
esis. We then examined an additional dataset to evaluate
the prognostic significance with regard to survival [14]
dataset. Table 1 describes these datasets in detail. The
Yu, Taylor and Wallace datasets were directly down-
loaded from the normalized form deposited in GEO. The
Glinsky dataset [14] was obtained from the author.
Pathway-level datasets
To aggregate the genes into pathway-level mechanisms,
we evaluated two different annotation repositories from
two very differing etiologies: Gene Ontology (GO) and
Cancer Modules (CM) [15]. Gene Ontology terms and
their mappings to human genes for human genes were
downloaded from National Center for Biotechnology
Information at (ftp://ftp.ncbi.nlm.nih.gov/gene/DATA/
gene2go.gz) on December 11, 2009. Cancer Modules
were downloaded from Broad Institute (c4.cgn.v3.0.sym-
bols.gmt on February 1, 2012).
GO relies on human curated annotations for determi-
nation of each pathway. In sharp contrast, Cancer Mod-
ules are a computationally derived set of pathways. The
CM’s are an integrated analysis of 1,975 published micro-
arrays spanning 22 tumor types divided into modules.
Each set of CM genes is derived from co-expression ana-
lyses that do not rely on curated knowledge or prior
genesets.
Gene Ontology is organized into three separate ontolo-
gies. We chose to use the Biological Process subset as it
had the appropriate scale of biology for pathway mechan-
isms. To avoid the oversampling bias introduced by multi-
ple alternate probe-sets assigned to a gene, we used the
probe-set of a gene with the largest coefficient of variation
and discarded the others. By this approach, we intended to
capture the gene most discriminative among diseases and
controls and filtered the false signals in validation stage.
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Generating FAIME-derived mechanisms via gene sets
FAIME uses mRNA expression arrays as input and as out-
put provides a score for each individual term for the gene
annotation set (GO, CM) desired. The specifics of the
algorithm have been described in detail previously[9]. For
simplicity, FAIME-derived Gene Ontology mechanisms
and Cancer Module mechanisms will be abbreviated
FD-GO and FD-CM, respectively. In brief, for a given
patient’s gene expression profile, all expressed genes are
sorted in a descending order according to the expression
level. An exponential decreasing weight (Eq. 1) is then
assigned to the ordered genes. The resultant weighted
expression values are used to prioritize these highly
expressed genes.
wg,s = (rg,s) · (e
−
rg,s
|G| ) (1)
Eq. 1. Weight rg,s assigned to gene g in total set of
array genes G for a patient sample s, where |G| is the
cardinality of G
NC(GOi,s) =
1
|GOi|
∑
g∈GOi
(wg,s) (2a)
NC(G/GOi,s) =
1
∣
∣G/GOi
∣
∣
∑
g∈G/GOi
(wg,s) (2b)
where G/GOi = {g|g /∈ GOi ∩ g ∈ G}
Eq. 2a, 2b. Normalized centroid NC(GOi,s), calculated
within sample s, using weighted expression of genes
associated to the Gene Ontology mechanism i. G/GOi, is
the complement of GOi genes in the array gene set G .
FMraw(GOi,s) = NC(GOi,s) − NC(G/GOi,s) (3a)
FM(GOi,s) = FMraw(GOi,s) − minj=1,2,... ,|M|
(
FMraw(GOj,s)
)
(3b)
Eq. 3. FM(GOi,s) is the FAIME score of Gene Ontology
mechanism i in sample s. M is the set of mechanisms in
GO; |M| is its cardinality. Cancer Module mechanisms are
similarly calculated for each sample.
For each annotation term (based on its gene members),
an average of the weighted expression values from the
individual patient is calculated (Eq. 2a). We then normal-
ize this annotation term score (Eq. 3a) by subtracting the
average of the complement set (genes NOT in the annota-
tion term) (Eq. 2b). This process is repeated for every
annotation term and for every patient. Finally, assuming
the majority of pathways unchanged between sample
groups, we run a within-sample normalization for these
calculated individualized FAIME scores. FAIME scores of
each sample are rescaled by using the minimum raw score
of each sample (Eq. 3b).
Derivation of FAIME tumorigenesis mechanisms (Table 2)
We compared individualized FAIME scores between two
cohorts of patients (tumor versus normal) for a given
dataset using a standard t-test. The resultant p-values
were adjusted for multiplicity using the Benjamini false
discovery rate (FDR) method. Terms with a FDR less
than 5% and 1% were respectively retained as two distinct
sets. We then carefully took note of the directionality of
the between group change per term, according to the
FAIME score per term. Specifically, a positive FAIME
score indicates that the majority of the gene members of
the measured pathway are up-regulated in tumor than in
normal samples. Thus, our final FAIME-based tumori-
genesis signature includes both an annotation term and
its associated vector.
Derivation of differentially expressed genes and Gene
Ontology enrichment (Table 2)
To derive a list of differentially expressed genes from each
of the datasets, we loaded the gene expression sets into R/
Bioconductor and performed standard log normalization.
We first filtered genes using a 2 fold-change cutoff, com-
paring tumor with normal samples. Highly differentially
expressed genes were identified using Significance Analysis
of Microarrays (SAM) algorithm in the Bioconductor sig-
genes package. SAM, by design, controls for multiplicity.
Genes with an FDR of 5% and 1% were retained. We then
performed Gene Ontology biological process pathway
Table 1 Prostate cancer datasets analyzed
Author Phenotype Samples Analyzed Usage Source
[11] Normal vs Tumor Authors examined 61 microdissected prostate cancer specimens along with 63 normal prostate
tissues samples adjacent to tumor of patients.
Feature
Selection
GDS2547
[12] Normal vs Tumor Authors examined 33 African-American and 36 European-American patients with prostate
cancer. Also profiled 18 non-tumor prostate tissues from 7 African-American and 11 European-
American patients.
Feature
Selection
GSE6956
[13] Normal vs Tumor Comprehensive set from Memorial Sloan Ketting tumor bank in prostate tumors from 53
patients with primary or metastatic prostate cancer and 29 normal controls.
Feature
Selection
GSE21032
[14] Disease free
interval survival
79 tumors were obtained from the Memorial Sloan Kettering tumor bank. The authors
identified three signatures of early recurrence (within one year).
Validation
Set
From
author
The first three datasets are used for mechanism feature selection reported in Table 2 and Figure 1. The fourth dataset serves as independent validation as
depicted in Figure 3.
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enrichment using the DAVID tool [16]. Finally, we kept
GO terms that met a FDR of less than or equal to 5%.
Determining pathway mechanism overlap across multiple
datasets (Table 3)
To compute mechanism overlap among our FAIME-
derived Cancer Module (FD-CM) and FAIME-derived
Gene Ontology (FD-GO), we took advantage of the fact
that FAIME mechanisms include both an annotation
term and a direction of deregulation. Thus, a biologically
meaningfully shared tumorigenesis mechanism between
two signatures must be similarly matched on both (as dif-
ferentially expressed FAIME scores can be either up- or
down-regulated, concordance of the direction of the
deregulation is required). To standardize the overlap
comparison in Table 3, we provide the overlap in terms
of percentage of each of the two original sets of deregu-
lated mechanisms being compared.
Determining significance of the FAIME-derived
mechanism overlap across multiple datasets and for
significance of overlap to known cancer genes
To compute the probability of FD-GO and FD-CM
mechanistic overlap, we first converted the mechanisms
to their constituent genes. We then used a bootstrap
method of 10,000 draws of genes from the same FD-GO
transformed background in R and from the FD-CM
transformed background. We then computed the number
of times the two sets overlapped at the desired target or
higher. An empirical p-value was estimated for the signif-
icance of cross-dataset overlap. Similarly, we evaluated
the genes overlapping between FD-GO and FD-CM with
that of known cancer genes from the Wellcome Trust
Sanger Institute Cancer Genome Project web site, http://
www.sanger.ac.uk/genetics/CGP on March 3, 2012. We
performed a bootstrap of 10,000 draws to generate an
empiric p-value to evaluate whether observed the overlap
between established cancer genes and the overlap could
have occurred by chance alone. The R algorithm for Par-
titioning Around Medoids (PAM) was utilized in a para-
meter-free way to automatically generate two unbiased
partitions from either the GO-terms or the “Cancer
Modules” features associated to tumorigenesis.
Results and discussion
FAIME-derived mechanisms are exquisitely sensitive to
phenotypic differences and provide greater coverage
than differential gene expression analysis
We first examined the differences between prostate
tumor and normal prostate. We used three independent
datasets and identified patient groups of interest in each:
Yu (109 samples), Wallace (69 samples), and Taylor (82
samples). We transformed the gene expression data into
FAIME-space using the procedure outlined in the Meth-
ods. As with previous FAIME-derived mechanism gen-
eration, we noted tremendous heterogeneity among the
datasets with regard to the highly variable number of sig-
nificant mechanisms. The Yu dataset resulted in the lar-
gest sets of mechanisms (as a percentage of the search
space) whereas the Wallace dataset consistently had the
shortest. As would be expected with traditional differen-
tially expressed gene sets generated using SAM at a FDR
of 5% and 1%, they consistently represented only a small
fraction of the original gene space from which they were
derived (less than 5%) (Table 2).
As a point of comparison with our FD-GO mechanisms,
we performed a standard bioinformatics Gene Ontology
enrichment of the differentially expressed genes for each
dataset. Interestingly, no terms were commonly identified
by the conventional enrichment analyses (FDR cutoff of
Table 2 Comparison of FAIME-prioritized mechanisms against controls (standard bioinformatics)
Human Prostate
Cancer Dataset
FDR FAIME-Derived Mechanisms Controls: Standard Bioinformatics
Approaches*
Gene Ontology (n = union of {4877
up-} ∪ {4877 down-} regulated)
Cancer Module (n = {454 up-}
∪ {454 down-} regulated)
Diff.
Expressed
Genes
GO Enrichment from Diff.
Expressed Genes (# terms;
n = 4877)
Yu 0.01 28% (2703) 25% (230) 2.3% (208/
8799)
0.3% (14)
0.05 32% (3137) 31% (282) 3.3% (293/
8799)
0.4% (21)
Wallace 0.01 5% (441) 4% (36) 2.5% (326/
12680)
0.1% (4)
0.05 13% (1226) 9% (83) 4.5% (574/
12680)
0.2% (10)
Taylor 0.01 17% (1672) 12% (109) 0.7% (202/
26448)
0.1% (6)
0.05 25% (2395) 19% (168) 1.0% (266/
26448)
0.2% (9)
*As a comparison, differentially expressed genes (SAM, FDR ≤ 0.05) were enriched for Gene Ontology (GO) Terms using the DAVID tool. Numbers in parentheses
indicate significant terms and the universe of terms from which they were drawn to generate the percentage indicated.
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5%). In contrast, FD-GO identified 13% to 48% overlap
between each pair of datasets and 6% of overlap across all
three datasets analyzed (Figure 1).
From this we concluded that FAIME-derived mechan-
isms are more reproducible among different experiments
pertaining to the same disease. Further, FAIME-based
methods provide an improvement in overall percentage
coverage and sensitivity even in the same pathway space.
Sets of FAIME-derived mechanisms overlap more than
sets of differentially expressed genes
A primary characteristic of mRNA based differentially gene
expression sets is their lack of consistency among datasets,
patients and methods of generation. Indeed, when we
explored the totality of differentially expressed genes at a
FDR less than 5% in the three datasets, only 7 genes over-
lapped after taking into account shared directionality.
Indeed, this pattern was repeated even when we examined
the Gene Ontology mechanisms that were derived from
direct enrichment of the differentially expressed sets of
genes. No Gene Ontology terms overlapped in a meaning-
ful manner (Figure 1, Table 3). In contrast, using FAIME,
we use the totality of the expressed genes without “cherry-
picking” them to develop mechanisms. To determine
whether our FAIME-derived mechanisms were better able
to detect common pathways between datasets we exam-
ined the percentage of genes that overlapped with the
mean size of the significant mechanisms from which they
were derived. At the overlap of all three datasets, were 14
FD-CM mechanisms (Supp Table 1 in Additional file 1),
137 FD-GO mechanisms (Supp Table 2 in Additional file
1), and conventional differentially expressed gene sets only
overlapped by 7 genes (Supp Table 3 in Additional file 1).
At face value, it may appear that the overlap of the differ-
ential expressed genes are meaningful, it is important to
take into account the background from which they were
derived - these overlap genes only represented about 1-3%
of the size each set of differentially expressed genes. In
comparison, the overlap FD-GO mechanisms overlapped
three times more at 4-11% and the FD-CM mechanism
overlapped even more so at 5-17%. In other words, despite
dataset heterogeneity, FAIME-derived pathway mechan-
isms increased three- to four-fold the overlap in all the
pairwise dataset comparisons. As an example, looking
across Table 3 at the Yu/Taylor dataset overlap, we see
FD-GO mechanisms overlapping at 30% and FD-CM
mechanisms at 34%. The differentially expressed gene set
overlapped at a mere 7%.
FAIME-derived mechanisms recapitulate and reveal novel
prostate cancer biology
Careful analysis of the overlap of the FAIME-derived
mechanisms reveals pathways that are known players in
tumorigenesis. For example, the top two pathways
Table 3 Evaluation of the overlap among different approaches to prioritize classifier’s mechanisms
Approaches to Prioritize Classifier’s Mechanisms Overlapping
Mechanism (#)
% of each
compared set
Overlapping p-
value (FET)
FAIME-Derived Approaches Overlap-Gene Ontology
Yu ∩ Wallace 462 15%; 38% 6.9 x10-6
Yu ∩ Taylor 824 26%;34% 3.8 x10-3
Wallace ∩ Taylor 360 29%;15% 2.2 x10-5
Yu ∩ Wallace ∩ Taylor 137 4%;11%;6%
Overlap Cancer Module
Yu ∩ Wallace 41 15%;49% 1.9x10-4
Yu ∩ Taylor 77 27%;46% 5.7 x10-6
Wallace ∩ Taylor 25 30%;15% 4.8 x10-4
Yu ∩ Wallace ∩ Taylor 14 5%;17%;8%
Controls: Standard Bioinformatics
Approaches
Overlap of Differentially Expressed Genes
Yu ∩ Wallace 33 11%;6% 6.1 x10-9
Yu ∩ Taylor 65 22%;24% <2 x10-16
Wallace ∩ Taylor 20 3%;8% 1.5 x10-3
Yu ∩ Wallace ∩ Taylor 7 2%;1%;3%
Overlap GO derived from Differentially
Expressed Genes
Yu ∩ Wallace 1 5%;10% 4.2 x10-2
Yu ∩ Taylor 0 NA NS
Wallace ∩ Taylor 0 NA NS
Yu ∩ Wallace ∩ Taylor 0 NA NS
Legend: NA = not applicable; NS = not significant; #= count of significant mechanisms overlap
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(smallest FDR value) that were increased in tumor relative
to normal tissue in the FD-GO mechanistic overlap were
GO:0040519 “negative regulation of nitric oxide biosyn-
thetic process” and GO:007260 “tyrosine phosphorylation
of STAT protein” (Supp Table 2 in Additional file 1).
Interestingly, nitric oxide negatively regulates androgen
receptor activity that is critical in all prostate cancer [17]
and has been explored as a potential therapeutic modality.
Figure 1 FAIME transformation of gene expression arrays into Gene Ontology space (Panel A) and Cancer Module Space (Panel B)
improves overlap by three to four fold as compared to standard bioinformatics techniques as demonstrated by differential gene
expression (Panel C) or Gene Ontology enrichment of the differentially expressed genes (Panel D). In this analysis, we compared 3
different prostate cancer datasets (Yu, Wallace, Taylor) for differences between tumor and normal prostate gene expression in 4 different analysis
spaces: Gene Ontology (Panel A), Cancer Modules (Panel B), standard differential genes (Panel C), and Gene Ontology terms derived from
standard differentially expressed genes (Panel D). Each Venn diagram displays how well how each independent mechanism set overlaps in each
of these spaces. The bold percentage in each panel provides the percentage of overlapping terms as a percentage of the average mechanism
set length. Panel C demonstrates conventionally generated differentially expressed genes using the Significance Analysis of Microrarrays with a
FDR of 5%. In panels A and B we first transform the gene expression arrays into either Biological Process Gene Ontology space or Cancer
Module space, respectively. Individual pathway terms were analyzed standard t-test and adjusted for multiplicity. Terms with a FDR ≤ 5% were
retained. The Gene Ontology terms in Panel D were generated by enriching the differentially expressed genes in Panel C using the DAVID tool
and retaining terms with a FDR ≤ 5%. Legend: *Only concordantly deregulated mechanisms across datasets are counted in FAIME (e.g.
significantly up-regulated ones in cancer against each other, then significantly down-regulated ones, then union of the two groups).
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Similarly, activation of the STAT family of transcription
factor by tyrosine kinases has been recognized informati-
cally by ourselves and others as key drivers in prostate
cancer [1,18].
Perhaps what is more interesting are the pathways
that are unexpected or poorly described in the prostate
cancer literature. Such an example may be GO:0019896
“axon transport of mitochondrion” which is hinted at by
previous studies of a class of drugs that inhibit this
pathway. Initial in vitro work has demonstrated anti-
tumor effects in prostate cancer [19]. Although this
potential biological drug class was identified, further
pursuit of understanding the biological mechanisms
underlying the role this pathway has not been further
researched in prostate cancer.
Similarly, while the FD-CM mechanisms do not have
formal associated annotations, they are informative as
well. For example, Module 457 (Supp Table 1 in Addi-
tional file 1) is composed of 10 genes that are upregu-
lated in prostate tumors as compared to normal tissue.
Yet Gene Ontology enrichment in either the Biological
Process or Molecular Function ontologies does not lead
to statistically significant enrichment. Nevertheless,
Module 457 contains the gene KPNA2 that has recently
been identified as a potential biomarker for recurrent
prostate disease [20]. KPNA2 is involved in nuclear
transport and the other genes in the module, such as
nucleolin, are part of the nuclear structure. The actual
mechanism to its oncogenic activity still needs to be
clarified. Thus a FAIME-derived Cancer Module
approach allows us to identify new pathways that may
not be fully elucidated or even discovered.
Curated GO and computationally generated “Cancer
Module” mechanisms overlap significantly and are
enriched for known prostate cancer genes
After determining that, indeed, FAIME-derived mechan-
isms improve overlap among different independent data-
sets, we next explored whether these FAIME-derived
mechanisms overlapped amongst themselves. In other
words, do mechanisms from FD-GO and FD-CM overlap
when we explore their shared common genes? To make
this determination, we mapped each FAIME-derived
overlap (the commonly shared mechanisms among all
three datasets) back to their constituent genes and then
examined their overlap. Figure 2 summarizes the results
of our analysis. We determined that 127 genes were
shared (empiric p-value: p < 0.0001) between the
Figure 2 FAIME-derived Gene Ontology and Cancer Module tumorigenesis mechanisms overlap significantly when we analyze their
constituent genes by a bootstrap method to generate an empiric p-value. 127 genes overlap between the two of them and are highly
enriched for known and novel deregulated prostate cancer pathways.
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overlapping FD-CM mechanisms and those derived from
the overlapping FD-GO mechanisms. We also examined
if there were differentially expressed genes that were
shared among the FD-GO and FD-CM mechanisms.
Indeed, we observed that JUNB, a transcription factor
that regulates growth response and has been implicated
in prostate cancer progression [21] was in common
among all three spaces.
We next proceeded to look more closely at the 127
genes shared by FD-GO and FD-CM (Supp Table 4 in
Additional file 1). We performed two analyses. First, we
asked whether or not these 127 genes were enriched for
known cancer genes. Using the Sanger Cancer Gene
Census, a curated list of known cancer genes (currently
474 genes), we determined that 14 genes overlapped sig-
nificantly (empiric p-value < 0.0001) between our 127
genes and the Cancer Gene Census. This gave us further
confidence that our method and the overlap genes were
indeed highly related to tumorigenesis.
In our second analysis, we used the DAVID tool and
determined the available annotations for this gene set.
The Kyoto Encyclopedia of Genes and Genomes (KEGG)
served as an independent source of pathway enrichment,
two cancer-related KEGG terms came up as significant
after correcting for multiplicity by Bonferonni, hsa05219:
“bladder cancer” (p = 0.003) and hsa05200: “pathways in
cancer” (p = 0.01). In addition, when we performed this
enrichment using Gene Ontology, the top term in the
Biological Process ontology was regulation of “cell prolif-
eration” (Bonferonni: p < 0.0001). Again, this is inline
with one of the key hallmarks of cancer. A complete list
of the statistically significant terms is available in Supp
Table 5 in Additional file 1.
FAIME-derived mechanisms of tumorigenesis are
predictive for prostate cancer recurrence
Because we generated our pathway mechanisms based
on the difference between normal prostate and prostate
cancer, we essentially developed a set of tumorigenesis
mechanisms. We subsequently hypothesized that men
with prostate cancer who developed recurrent disease
would have greater deregulation of this tumorigenesis
set. To test this hypothesis, we examined a well-anno-
tated dataset of 79 men who underwent prostatectomy
[14] and were followed until biochemical relapse
(detectable prostate specific antigen). In these patients,
PSA is a well-validated, powerful indicator predictor of
prostate cancer progression (http://www.mskcc.org/can-
cer-care/adult/prostate/prediction-tools). In each of
these cases, “pre-treatment”, “post-prostatectomy”, “sal-
vage radiation” – PSA values are critical for prediction
of outcome. In patients who have had their entire pros-
tate and associated cancer removed, the PSA should be
undetectable. Thus, in later tests, if the PSA becomes
detectable, this detection is termed “biochemical recur-
rence” of the prostate cancer.
We divided these men into two separate cohorts using
the PAM algorithm using either the mechanisms from
the FD-GO and the FD-CM overlaps. Kaplan-Meier ana-
lysis of the Glinsky dataset in Gene Ontology and Cancer
Module space demonstrated a statistically different recur-
rence free interval (p = 0.039 and 0.018, respectively).
Impressively, as seen in Figure 3, in the good prognosis
cohort of the Kaplan-Meier curves, the 50% recurrence
endpoint was not reached in either pathway mechanism
set.
Discussion
The relative overlap of mechanisms discovered between
different prostate cancer cohorts appears modest, however
the absolute overlap corresponds to 137 GO terms and 14
cancer modules. These somewhat small overlaps can be
interpreted in the context of highly heterogeneous popula-
tions of prostate cancer patients. This dataset heterogene-
ity has also been reported as a fundamental challenge in
reproducibility of gene signatures across solid tumor data-
sets and the FAIME methodology was nonetheless sensi-
tive enough to significantly detect them. Here, we
document at least four sources of heterogeneity as con-
founders in the results. First, Yu’s samples are laser-micro-
dissected and thus have no stromal expression whereas
the Taylor dataset only required >70% cancer cells -as
assessed by histology- thus allowing for ~30% stromal
cells influence on the array expression. In a separate publi-
cation we have demonstrated that this change is profound
and may mask or confound signal [22]. In the case of the
Wallace dataset, we know that African-descent men com-
prise ~50% of the sample set. And indeed black men have
a far higher rate of prostate cancer than European-descent
men and are twice as likely as whites to die of the disease.
Multiple publications (including Wallace et al.) have tried
to define the set of genetic determinants that underlie
this disparity. Unsurprisingly, FAIME detected a different
set of enriched pathways than the other two (mostly
European) sets - and this is the largest gap concordantly
observed in term of GO as well as Cancer Modules
mechanisms (Table 3). Furthermore, heterogeneity lies in
dates and platforms for gene expression analysis. The Yu
dataset published in 2004 uses different array technology
than that of Taylor [13]. Although the techniques are simi-
lar, the reagents, probes, and chips have undergone a
refinement process what amounts to over half a decade. In
total, we, like the SAM, methodology are beholden to the
underlying fundamentals of the datasets analyzed. Indeed,
our previous work exploring non-overlapping gene expres-
sion signatures despite overlapping phenotypes [1] points
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to the need for more sensitive techniques, such as FAIME
to be employed. Thus, the apparent decrease in specificity
in mechanism detection prostate cancer as compared to
that reported earlier in head and neck cancer [9], is most
likely attributable to increased heterogeneity in prostate
cancer datasets.
Computationally derived gene sets (e.g. “Cancer Mod-
ules”) potentially lack one simple interpretation. Indeed,
computationally-defined mechanisms may cross over or
include co-expressed pathways that biologists may have
envisioned as two different mechanisms. However, it is
important to remember that this distinction was at a biol-
ogist’s discretion or conceptualization. Computationally
mechanisms that are unbiased may be closer to true tran-
scriptome reality.
Another limitation is that the choice of size of the gene
set to define a mechanism is in of itself open to debate.
The determination of the statistical test used may also
alter the results of a FAIME analysis. Taken together, the
fundamental limitation of our methodology is that we are
beholden to a priori defined mechanisms. The quality and
context in which these gene sets/mechanisms are gener-
ated will ultimately affect our results.
Despite these limitations, computationally-generated
gene sets still have the advantage of being generated in a
principled, consistent, and unbiased manner. Researchers
also have the ability to recreate computationally-generated
sets as needed for differing situations, a process to which
standard curated pathway mechanisms would not be
amenable.
Future directions
The combination of the FAIME algorithm using compu-
tationally defined mechanism is a natural fit for the
deluge of next-generation sequencing data that is rapidly
being generated. For example, RNA-seq technology
identifies not only the level of transcription but also
transcriptional variants (e.g. splice variants of the andro-
gen receptor in prostate cancer) that may have differing
phenotypic consequences. These gene variations are not
accounted for in traditional pathway analysis using
curated databases of mechanisms. In fact, it is unlikely
there will be a human curated database in the short-
term that will be able to maintain pace. Therefore, an
agnostic, computational approach that is scalable, robust
and reduces dimensionally in an efficient manner is
essential.
We believe that our FAIME/computationally-defined
mechanism paradigm will help address this. To this end,
we are currently evaluating RNA-seq datasets in prostate
cancer to test this hypothesis. By developing our own
computational-defined mechanisms and then applying
FAIME, we take advantage of all the patient prostate can-
cer data - not just explore genes or alleles with which we
are familiar. Then by applying the FAIME algorithm, we
can apply our mechanisms to individual patients - possibly
for treatment decisions and/or improved risk stratification.
Finally, improved detection of unbiased genesets have
recently been proposed and will systematically be investi-
gated and contrasted against one another and the curated
ones for utility in deriving classifiers of response to
Figure 3 Kaplan-Meier plots of recurrent prostate cancer using the FAIME-derived Cancer Module overlap set (Panel A) and the
FAIME-derived Gene Ontology overlap set (Panel B). PAM analysis was used to divide patients into two cohorts. Statistically significant
differences in time to recurrence are consistently observed based on log-rank statistic (p = 0.0186 and 0.0392, respectively).
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therapy: (i) differential interaction modules from Chen’s
group [23], (ii) dynamic transcriptional networks [24], (iii)
genetic-expression interactions modules [25,26], etc.
Conclusion
The extension of our FAIME methodology with curation-
free biomodules ("Cancer Module”) derived from the
dynamic and congruent activation and/or deactivation of
gene expression across numerous cancers breaks from the
paradigm of recapitulating the known curated pathway
mechanism universe. Furthermore, it empowers us to dis-
cover mechanistic deregulations that may be poorly char-
acterized or even unknown. We demonstrate the utility
and power of transforming gene expression arrays into
unbiased pathway spaces comparable in accuracy to the
FAIME-transformation using Gene Ontology that we had
previously validated in head and neck and lung cancers.
Pathway-derived mechanisms have the advantages of
decreasing the overall dimensionality of the search space
while increasing the sensitivity of detecting phenotypic dif-
ferences. This allows for additional statistical power for
exploring complex interactions of genes as compound bio-
markers, as demonstrated by MammaPrint [27] and Onco-
type DX [28] for breast cancers. As expected, we clearly
demonstrate that mechanism-level overlap trumps gene-
level overlap despite dataset heterogeneity, and this for
both types of mechanisms: curated and curation-free ones.
As mentioned, while they may lack clear functional classi-
fications, computationally generated mechanisms, such as
the Cancer Modules, recapitulate (i) known cancer genes,
(ii) those predicted with curated GO pathways, and (iii)
additionally provide coverage of genes that have yet to
have a function assigned and would not have been discov-
ered with the curated pathway paradigm.
Finally, in our application to prostate cancer, we demon-
strate that either Gene Ontology or Cancer Module con-
ceptualizations of a molecular pathway provide excellent
discriminatory ability between normal prostate and tumor.
These pathway mechanisms are of indisputable prognostic
import when applied to independent clinical datasets.
Because these pathway mechanisms can be applied at the
individual patient level, a natural extension of this technol-
ogy would be to develop customized predictors for recur-
rence and for survival. Thus, as the number and function
of genes multiplies, pathway level mechanisms may ulti-
mately become the de facto modality to interpret molecu-
lar deregulations in a convenient, quantitative and
biologically anchored fashion.
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